ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >protein tyrosine kinase >CO-1686


CO-1686 Suppliers list
Company Name: Shanghai Bojing Chemical Co.,Ltd.
Tel: +86-21-37122233
Products Intro: Product Name:CO-1686
Purity:99% Package:1kg;25kg;200kg Cardboard barrels Remarks:White powder
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:1374640-70-6
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Shanghai Yingrui Biopharma Co., Ltd.
Tel: +86-21-33585366
Products Intro: Product Name:N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-Methoxyphenyl]aMino]-5-(trifluoroMethyl)-4-pyriMidinyl]aMino]phenyl]-2-propenaMide
Purity:99% Package:100g;500g;1kg;25kg...
Company Name: Nanjing Finetech Chemical Co., Ltd.
Tel: 025-85710122 17714198479
Products Intro: Product Name:Rociletinib
Purity:99%min Package:1KG;10KG;100KG;500KG;100g Remarks:ISO certified
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: Product Name:CO-1686
Purity:0.99 Package:5MG;10MG;50MG;100MG,1G,5G

Lastest Price from CO-1686 manufacturers

  • CO-1686
  • US $7.00 / KG
  • 2019-07-06
  • CAS: 1374640-70-6
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 1000KG
  • CO-1686
  • US $1.00 / KG
  • 2019-07-06
  • CAS:1374640-70-6
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 1000KG
CO-1686 Basic information
Anti-cancer drugs Biological activity In vitro study In vivo studies Synthesis method
Product Name:CO-1686
Synonyms:CO-1686;AVL-301;CNX-419;CO-1686 (AVL-301);CO-1686/CO1686;N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide;Clovis CO-1686;CO-1686(free base)
Product Categories:Inhibitors;API
Mol File:1374640-70-6.mol
CO-1686 Structure
CO-1686 Chemical Properties
density 1.372±0.06 g/cm3(Predicted)
CAS DataBase Reference1374640-70-6
Safety Information
Risk Statements 23-25-36
Safety Statements 24
HS Code 29335990
MSDS Information
CO-1686 Usage And Synthesis
Anti-cancer drugsOn May 20, 2014, Clovis Oncology announced that the US FDA had granted its test drug CO-1686 for breakthrough treatment drug qualification, as a second line, single administrated drug for the treatment of EFGR mutation non-small cell lung cancer (NSCLC) of the T790M mutation patients. The awarding for this breakthrough therapeutic drug eligibility was based on the efficacy and safety results of Co-1686 in an ongoing Phase 1/2 study. Data of related study have shown that CO-1686 is a third-generation EGFR inhibitor, being used for the treatment of non-small cell lung cancer, overcoming the drug resistance generated from the EGFR T790M mutations, and has excellent efficacy and tolerability on NSCLC with T790M + EGFR mutations. Its major market competitor, the third-generation EGFR inhibitor, AZD9291 (AstraZeneca) has also gained FDA's groundbreaking drug eligibility.
CO-1686 is a novel, oral-administrated, targeted covalent (irreversible) inhibitor of the epidermal growth factor receptor (EGFR) mutations, being able to suppress key activation mutations and T790 drug-resistant mutations, leaving the wild-type EGFR signal unused. This drug was developed for the treatment of NSCLC patients carrying initially activated EGFR mutations and major resistant mutant T790M.
The above information is compiled and edited by Xiao Nan of Chemicalbook.
Biological activityRociletinib (CO-1686, AVL-301) is an irreversible, mutation-selective EGFR inhibitor that targets EGFRL858R/T790M and EGFRWT with a Ki of 21.5 nM and 303.3 nM, respectively. Phase 2.
Target: EGFR (L858R/T790M) EGFR (wt)
IC50: 21.5 nM (Ki) 303.3 nM (Ki)
In vitro studyCO-1686 inhibited the p-EGFR in EGFR-expressing cells with an IC50 ranging from 62 to 187 nM while inhibiting EGFR phosphorylation. In three WT EGFR-expressing cells, the IC50 is larger than 2,000 nM. CO-1686 can selectively inhibit the growth of mutant EGFR expressing NSCLC cells with a GI50 ranging from 7 to 32 nM while inducing apoptosis. The CO-1686-resistant NSCLC cell line exhibited a signal for epithelial-mesenchymal transition and increased susceptibility to AKT inhibitors.
In vivo studiesIn all EGFR mutant models, as well as in transgenic mice expressing human EGFRL858R-and EGFRL858R/T790M, CO-1686 caused significant tumor growth inhibition in a dose-dependent manner.
Synthesis method5-fluoro-2-nitroanisole was condensed with piperazine, acetylated and reduced to give 1-(3-methoxy-4-aminophenyl)-4-acetylpiperazine (4) In addition, use 2, 4-dichloro-5-trifluoro methyl pyrimidine to undergo condensation with 3-nitroaniline, reduction and amidation to obtain N-[3-(2-Chloro-5-trifluoromethyl-pyrimidin-4-amino) phenyl] acrylamide (7). 4 and 7 were condensed to give the EGFR inhibitor, the anticancer drug CO-1686 with a total yield of about 71% (based on 2, 4-dichloro-5-trifluoromethyl pyrimidine).
Reference: Synthesis of CO-1686 [J]. Chinese Pharmaceutical Industry, 2014, 45 (8): 710-713.
OF: (1) Lai Yisheng, male, professor, doctoral supervisor, engaged in anti-inflammatory and anti-tumor drugs studied. (2) Zhang Shan, female, graduate students, professional direction: medicinal chemistry.
Tag:CO-1686(1374640-70-6) Related Product Information
Genistein Afatinib Dacomitinib Irbinitinib Volitinib Olmutinib XL-647 AZD 3759 AG 1478 HYDROCHLORIDE OSI-420 Anlotinib EGF816 Neratinib Poziotinib (HM781-36B) Ibrutinib AZD-9291 AVL-292 N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide